Thermo Fisher CEO Says Orders Outpacing Revenue and AI Is Compressing Drug Development Timelines

Thermo Fisher Scientific CEO Marc Casper told the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 that the company is seeing orders outpace revenue, a forward-looking signal he said bodes well for future growth. The commentary marked an acceleration in business momentum, with Casper indicating that growth is gathering pace heading into the remainder of the year.

Casper highlighted artificial intelligence as a meaningful force reshaping the pharmaceutical industry, saying AI is shortening the time to market for medicines that prove effective. That development is relevant for Thermo Fisher because faster drug development pipelines translate into increased demand for the company's research tools, lab equipment, and contract manufacturing services.

The order-book strength, combined with an improving biopharma environment that has weighed on the company in recent years following a post-COVID correction in life science spending, suggests Thermo Fisher is moving into a more favorable demand environment. Management's conference remarks signal growing confidence that revenue growth will follow the order trend in coming quarters.